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75 
ARTICLE 
 
Dying to Be Fresh and Clean? Toxicants in 
Personal Care Products, the Impact on 
Cancer Risk, and Epigenetic Damage 
KATHERINE DRABIAK 
The FDA does not conduct pre-market review of chemicals con-
tained in cosmetics—which encompasses not only makeup but also 
numerous personal care products including shampoo, lotion, per-
fume, aftershave, and shaving cream. Every day, consumers use 
cosmetic products that contain a variety of synthetic ingredients, 
none of which the FDA has approved for safety but each of which 
are being ingested, absorbed, and inhaled into our bodies and ac-
cumulating in our tissue. Many of these products contain endocrine 
disrupting chemicals (“EDCs”), which emerging research links to 
an increased risk of cancer as well as immune and neurological dys-
function. This Article examines how the current risk-based regula-
tory system enables manufacturers to market products containing 
toxicants that cause preventable cancer while promising product 
safety. In addition to increasing cancer risk, EDCs have the poten-
tial to induce both epigenetic marks and transgenerational epige-
netic damage, increasing the risk of cancer and widespread adverse 
health consequences for future generations never exposed to the tox-
icant. This Article asserts that we have an ethical duty to enact pre-
cautionary regulations governing cosmetics that would protect the 
integrity of the human genome against preventable, environmen-
tally mediated damage. 
  
 
  Katherine Drabiak, JD is an Assistant Professor in the College of Public 
Health at the University of South Florida HEALTH. She may be contacted 
at kdrabiak@health.usf.edu. 
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I. INTRODUCTION 
In 2016, a jury in St. Louis awarded an unprecedented $72 
million verdict against consumer product giant Johnson & Johnson 
in a lawsuit over one of the most ubiquitous and recognizable 
2https://digitalcommons.pace.edu/pelr/vol35/iss1/2
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household products: Johnson’s Baby Powder.1 Class action plain-
tiffs in the lawsuit, Hogans v. Johnson & Johnson, asserted that 
Johnson & Johnson was aware of scientific evidence linking peri-
neal use of the talc in Johnson’s Baby Powder and Shower to 
Shower to an increased risk of ovarian cancer, but continued mar-
keting its products as safe while actively working to expand its 
market.2 Hogans raised media attention to a mistaken presump-
tion made by the public: if a personal care product is on store 
shelves, it must be safe.3 Contrary to popular belief, the FDA does 
not conduct pre-market review of chemicals contained in cosmet-
ics—which encompasses not only makeup but also numerous per-
sonal care products like shampoo, lotion, perfume, aftershave, and 
shaving cream.4 Every day, consumers use an average of twelve 
cosmetic products that contain a variety of synthetic ingredients, 
none of which the FDA has approved for safety but each of which 
is being ingested, inhaled, and absorbed into our bodies and accu-
mulating in our tissue.5 
Data from the National Biomonitoring Program administered 
by the Centers for Disease Control and Prevention has found more 
than 260 environmental chemicals in the human body, many of 
which are also found in the umbilical cord blood of newborns.6 
 
1.  Roni Caryn Rabin, Lawsuits Over Baby Powder Raise Questions About Can-
cer Risk, N.Y. TIMES (May 23, 2016, 3:41 PM), http://perma.cc/F7RW-F6X4; 
Jonathan Stempel, J&J Must Pay $72 million for Cancer Death Linked to 
Talcum Powder, REUTERS (Feb. 23, 2016, 11:54 AM), http://perma.cc/D7M4-
QP3H. 
2.  Amended Complaint & Demand for Jury Trial at 48, Hogans v. Johnson & 
Johnson, No. 1422-CC09012 (C.C. Mo. June 23, 2014) [hereinafter Amended 
Complaint]. 
3.  See Susan Berfield et al., Johnson & Johnson Has a Baby Powder Problem, 
BLOOMBERG (Mar. 31, 2016), https://perma.cc/5CTA-JKYS. 
4.  FDA Authority Over Cosmetics: How Cosmetics Are Not FDA Approved, But 
Are FDA Regulated, FDA (last updated Nov. 15, 2016), 
https://perma.cc/9CCJ-UEVC [hereinafter FDA Authority Over Cosmetics]. 
5.  SHARIMA RASANAYAGAM ET AL., CAMPAIGN FOR SAFE COSMETICS, ANTI-AGING 
SECRETS EXPOSED: CHEMICAL LINKED TO BREAST CANCER IN SKIN CARE 1, 7 
(2015), https://perma.cc/LH9H-SGRC [hereinafter RASANAYAGAM ET AL.] 
(discussing statistics on consumer product use); HEATHER SARANTIS ET AL., 
CAMPAIGN FOR SAFE COSMETICS & ENVTL. WORKING GRP., NOT SO SEXY: THE 
HEALTH RISKS OF SECRET CHEMICALS IN FRAGRANCE 1, 6 (2010), 
https://perma.cc/W55Q-K9FB [hereinafter SARANTIS ET AL.] (discussing ab-
sorption). 
6.  See CTRS. FOR DISEASE CONTROL & PREVENTION, FOURTH NATIONAL REPORT 
ON HUMAN EXPOSURE TO ENVIRONMENTAL CHEMICALS (2009), 
3
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Scientists from the Halifax Project suggest that many of these syn-
thetic chemicals contribute significantly to the rising rates of can-
cer in the past several decades.7 Despite substantial media atten-
tion to heritable risk for cancer, only 5 to 10% of all cancer cases 
have a genetic basis.8 In 2010, the President’s Cancer Panel af-
firmed the substantial environmental contribution to cancer risk, 
asserting that cancer prevention efforts have been insufficient and 
that we should increase awareness of the true magnitude of pre-
ventable risk from environmental carcinogens in consumer prod-
ucts.9 
Several stakeholders including corporate interests strategi-
cally exploit the current regulatory shortcomings governing cos-
metics. To the public’s detriment, these entities misrepresent the 
evidentiary standards set forth by the reigning risk-based ap-
proach to undermine scientific research demonstrating potential 
harm from toxicants in cosmetic products.10 Scientists are learning 
that the toxicants contained in cosmetics can not only contribute 
to risk of cancer but also induce epigenetic marks that cause dys-
function across the genome.11 Problematically, this damage affects 
 
https://perma.cc/TGA6-AEF6 [hereinafter FOURTH NATIONAL REPORT]; CTRS. 
FOR DISEASE CONTROL & PREVENTION, FOURTH NATIONAL REPORT ON HUMAN 
EXPOSURE TO ENVIRONMENTAL CHEMICALS, UPDATED TABLES (2015), 
https://perma.cc/VN3T-L2FS [hereinafter UPDATED TABLES]. 
7.  CURT DELLAVALLE, ENVTL. WORKING GRP., RETHINKING CARCINOGENS: NEW 
VIEW OF CANCER DEVELOPMENT FOCUSES ON SUBTLE, COMBINED EFFECTS 3 
(2015), https://perma.cc/9GN6-FC2Y [hereinafter DELLAVALLE]. 
8.  The Genetics of Cancer, NATIONAL CANCER INSTITUTE, 
https://perma.cc/JE4R-868H (last updated May 1, 2017); Angelina Jolie, My 
Medical Choice, N.Y. TIMES (May 14, 2013), https://perma.cc/YQH3-2KNB; 
Angelina Jolie Pitt, Diary of a Surgery, N.Y. TIMES (Mar. 24, 2015), 
https://perma.cc/RDA6-DRE2. 
9.  SUZANNE H. REUBEN ET AL., PRESIDENT’S CANCER PANEL, U.S. DEP’T HEALTH 
& HUMAN SERVS., REDUCING ENVIRONMENTAL CANCER RISK: WHAT WE CAN 
DO NOW (2010), https://perma.cc/6VTX-AX2Q [hereinafter PRESIDENT’S 
CANCER PANEL]. 
10.  See infra Part III. 
11.  Arline T. Geronimus, Deep Integration: Letting the Epigenome Out of the 
Bottle Without Losing Sight of the Structural Origins of Population Health, 
103 AM. J. PUB. HEALTH S1, S56–63 (2013); Mark A. Rothstein et al., The 
Ghost in Our Genes: Legal and Ethical Implications of Epigenetics, 19 
HEALTH MATRIX 1, 3–4 (2009); Mitchell S. Turker, Banning Bisphenol A in 
the United States and Canada: Epigenetic Science, The Precautionary Prin-
ciple, and a Missed Opportunity to Protect the Fetus, 8 J. HEALTH & 
BIOMEDICAL L. 173, 175–78 (2012); Christopher J. Wiener, 
4https://digitalcommons.pace.edu/pelr/vol35/iss1/2
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not only the current generation but may imprint the legacy of tox-
icants into our descendants’ genome, increasing their risk for can-
cer as well as endocrine, neurological, and reproductive impair-
ment.12 We have a duty to both present and future generations to 
mitigate preventable environmental contributors to cancer and ad-
vocate for a more stringent regulatory structure governing cosmet-
ics. 
II.  DYING TO BE FRESH AND CLEAN: TOXIC 
INGREDIENTS IN COSMETICS AND RISK OF 
CANCER 
A. Hogans v. Johnson & Johnson 
Deane Berg of South Dakota had been using Johnson’s Baby 
Powder in her perineal area for decades when she discovered she 
had ovarian cancer.13 In 2013, Berg filed suit against Johnson & 
Johnson, alleging a causal connection between using Johnson’s 
Baby Powder and her ovarian cancer.14 At trial, Berg’s attorneys 
introduced expert testimony from Dr. Daniel Cramer, who pre-
sented his independent research demonstrating a 33% increased 
risk of ovarian cancer for women who used talcum powder in the 
genital area.15 Berg’s attorneys also introduced evidence of talc’s 
immunotoxic and immunosuppressive properties that could con-
tribute to cancer-causing inflammation, which was bolstered by 
the pathologist’s report finding talc particles embedded in Berg’s 
ovarian tissue.16 Accompanying his oral testimony, Dr. Cramer 
submitted into evidence a written report that summarized over 
 
Transgenerational Tort Liability for Epigenetic Disease, 13 DEPAUL J. 
HEALTH CARE L. 319, 320–23 (2011). 
12.  David Crews & Andrea C. Gore, Transgenerational Epigenetics: Current 
Controversies and Debates, in TRANSGENERATIONAL EPIGENETICS 371, 377–
79 (Trygve Tollefsbol ed., 2014); Matthew D. Anway et al., Epigenetic 
Transgenerational Actions of Endocrine Disruptors and Male Fertility, 308 
SCIENCE 1466, 1466 (2005); Laura Rozek et al., Epigenetics: Relevance and 
Implications for Public Health, 35 ANN. REV. PUB. HEALTH 105, 107–10 
(2014). 
13.  Rabin, supra note 1. 
14.  Berg v. Johnson & Johnson, 983 F. Supp. 2d 1151, 1154 (D.S.D. 2013).   
15.  Id. at 1155–56, 1160–61; Plaintiff’s Expert Testimony Report by Dr. Daniel 
Cramer at 9, Berg, 983 F. Supp. 2d 1151 [hereinafter Cramer’s Testimony]. 
16.  Berg, F. Supp. 2d at 1155. 
5
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twenty additional studies demonstrating a significant increase in 
the risk of ovarian cancer associated with perineal talc use.17 The 
jury found in Berg’s favor, concluding that Johnson’s Baby Powder 
was unreasonably dangerous and that Johnson & Johnson failed 
to warn of the dangers associated with its use.18 Despite this con-
clusion, the jury elected not to award any damages to Berg.19 
Three years later in the spring of 2016, America’s most trusted 
brand was again under fire as media outlets, health groups, and 
environmental advocates began to question the talc used in John-
son’s Baby Powder and Shower to Shower.20 Like Berg, plaintiffs 
in Hogans v. Johnson & Johnson all used Johnson’s Baby Powder 
or Shower to Shower for decades, all developed ovarian cancer, 
and, as a class, alleged a causal link between their use of these 
products and the development of their cancer.21 For many women, 
including the 57 plaintiffs in Hogans, dusting talc in the genital 
area for feminine “freshness” was merely another part of their cus-
tomary practice.22 In advertising campaigns, Johnson & Johnson 
specifically marketed Johnson’s Baby Powder to adult women 
through the tagline: “for you, use every day to help feel soft, fresh, 
and comfortable,” while promising it is “clinically proven gentle 
and mild.”23 A surviving son of one of the plaintiffs who passed 
away from ovarian cancer expressed dismay: “It has to be safe. It’s 
put on babies. It’s been around forever. Why haven’t we heard of 
any ill effects?”24 This disbelief highlighted the massive disconnect 
between Johnson & Johnson’s advertising promising product 
safety and its simultaneous strategizing to refute credible evidence 
linking product use to ovarian cancer. 
Plaintiffs’ exhibits also brought to the forefront the ethical is-
sue of marketing a product that may increase risk of cancer to a 
market segment with pre-existing health disparities. Integration 
of Johnson’s Baby Powder into women’s daily routines is stratified 
 
17.  Cramer’s Testimony, supra note 15, at 4. 
18. Rabin, supra note 1. 
19.  Id.  
20.  STACY MALKAN, CAMPAIGN FOR SAFE COSMETICS, BABY’S TUB IS STILL TOXIC 
4–5 (2011), https://perma.cc/4NG9-6RTA; Berfield et al., supra note 3; 
Rabin, supra note 1.  
21.  Amended Complaint, supra note 2, at 53. 
22.  Id. at 19–20, 48; Berfield et al., supra note 3; Rabin, supra note 1. 
23.  Amended Complaint, supra note 2, at 47–48. 
24.  Berfield et al., supra note 3. 
6https://digitalcommons.pace.edu/pelr/vol35/iss1/2
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by race: Johnson & Johnson’s own marketing statistics demon-
strate greater use among black and Hispanic women.25 Internal 
memoranda demonstrated that Johnson & Johnson attempted to 
target this market segment with advertising campaigns in the 
1990s designed to increase minority product uptake and counter 
negative publicity surrounding the link between talc use and can-
cer.26 While this move capitalized on the minority market share, 
Plaintiffs attacked this strategy, alleging that Johnson & Johnson 
committed further ethical breaches by encouraging use of products 
containing toxicants that would increase existing health dispari-
ties27 in ovarian cancer.28 
According to Plaintiffs in Hogans, Johnson & Johnson acted to 
deliberately ensure the public would not become aware of adverse 
health risks.29 Plaintiffs asserted that, not only did Johnson & 
Johnson manufacture an unreasonably dangerous product and fail 
to warn consumers of the increased risk of cancer, but the company 
procured and disseminated “false, misleading, and biased infor-
mation regarding the safety” of talc to the public and regulatory 
bodies that rose to the level of civil conspiracy.30 Through discov-
ery, Plaintiffs’ attorneys uncovered damaging memoranda be-
tween Johnson & Johnson and an independent toxicologist sug-
gesting that Johnson & Johnson was aware of the risk of ovarian 
cancer from perineal talc use but deliberately attempted to 
 
25.  Id.  
26.  Id. 
27.  See Robert E. Bristow et al., Disparities in Ovarian Cancer Care Quality and 
Survival According to Race and Socioeconomic Status, 105 J. NAT’L CANCER 
INST. 823, 823 (2013); Cancer Health Disparities Research, NAT’L CANCER 
INST., https://perma.cc/3KXK-QGFU (last updated July 24, 2017); see also 
Kim Pearson, Chemical Kids, 24 TEXAS J. WOMEN, GENDER & L. 67, 85–86 
(2014) (discussing educational and financial barriers stratified by race and 
class for parents attempting to select products that do not contain toxicants 
to use for their children); Rajiv Shah & Kelly E. Taylor, Concealing Danger: 
How the Regulation of Cosmetics in the United States Puts Consumers at 
Risk, 23 FORDHAM ENVTL. L. REV. 203, 211–14 (2012) (discussing racially 
stratified health risks of using hair relaxers containing toxicants).  
28.  Amended Complaint, supra note 2, at 8; Martha Neil, St. Louis Jury Says 
J&J Must Pay $72M to Family to Dead Woman in Landmark Talcum Pow-
der Cancer Case, ABA JOURNAL (Feb. 23, 2016), https://perma.cc/34PJ-
X9EN. 
29.  Amended Complaint, supra note 2, at 49. 
30.  Id. at 51, 58–61. 
7
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mischaracterize the conclusions of data by denying such risk.31 In 
these memoranda, Johnson & Johnson’s independent toxicologist 
warned the Manager of Preclinical Toxicology that Johnson & 
Johnson’s assertion that lifetime exposure to talc by skin contact 
presents no significant risk of ovarian cancer is “outright false,” 
and that the company’s admission that although a weak associa-
tion might exist, “studies are insufficient to demonstrate any real 
association,” is inaccurate.32 Perhaps most damning, this inde-
pendent expert likened these blatant mischaracterizations to Big 
Tobacco denying the increased risk of lung cancer from smoking 
cigarettes.33 
Despite the International Agency for Research on Cancer’s 
(“IARC”) 2006 classification of perineal talc use as possibly carcino-
genic to humans,34 Johnson & Johnson swiftly responded to defend 
its reputation.35 Johnson & Johnson claimed that the jury verdict 
in Hogans “goes against decades of sound science”36 and that “the 
safety of talc is based on a long history of safe use and more than 
30 years of research.”37 Additional parties have filed lawsuits 
against Johnson & Johnson with similar claims while Johnson & 
Johnson continues to deny wrongdoing, referring to a 2014 FDA 
statement finding no conclusive evidence of a link between talc and 
increased risk of ovarian cancer.38 This reference, however, perpet-
uates the misunderstanding of the current principles governing 
regulatory risk analysis of cosmetics; an agency statement of a lack 
of conclusive evidence does not equate to product safety. 
 
31.  See id. at 59. 
32.  Letter from Dr. Alfred P. Whener (Exhibit 20) at 1–2, Hogans v. Johnson & 
Johnson, No. 1422-CC09012 (C.C. Mo. June 23, 2014). 
33. Id. at 2. 
34.  Amended Complaint, supra note 2, at 50 (citing International Agency for 
Research on Cancer, IARC MONOGRAPHS ON THE EVALUATION OF 
CARCINOGENIC RISKS TO HUMANS: CARBON BLACK, TITANIUM DIOXIDE AND 
TALC, WORLD HEALTH ORG. 412 (2010)). 
35.  See Press Release, The Facts About Talc Safety, JOHNSON & JOHNSON (Feb. 
24, 2016), https://perma.cc/29NB-AH54. 
36.  Associated Press, Johnson & Johnson To Pay $72m In Case Linking Baby 
Powder to Ovarian Cancer, GUARDIAN (Feb. 23 2016, 7:32 PM), 
https://perma.cc/ZTR6-TFKK. 
37.  The Facts about Talc Safety, supra note 35.  
38.  David Siegel, Johnson & Johnson Rocked by $55M Verdict in Talcum Pow-
der Cancer Trial, COURTROOM VIEW NETWORK (May 2, 2016, 9:17 PM), 
https://perma.cc/75ZD-XNY3. 
8https://digitalcommons.pace.edu/pelr/vol35/iss1/2
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B.  The Tip of the Iceberg: Toxicants in Cosmetics as 
Preventable Risk Factors for Cancer 
1.  Cancer as Public Health Concern 
The lawsuits against Johnson & Johnson brought attention to 
more substantial issues: First, the routine cosmetic products we 
use every day are likely contributing to an increased risk for cancer 
that is otherwise preventable.39 Second, it is probable that the pub-
lic is unaware of FDA’s lack of stringency pertaining to cosmetics 
and the risk of their toxic ingredients.40 In the past several dec-
ades, we have witnessed a staggering increase in a variety of can-
cers, including childhood cancer, that correlates to the increase in 
synthetic chemicals like those in cosmetics.41 
Cancer represents a significant public health issue: 41% of the 
U.S. population will be diagnosed with cancer at some point in 
their lives, and 21% will die from cancer.42 Cancer is costly,43 phys-
ically and emotionally devastating,44 and current treatments can 
introduce secondary morbidities.45 Contrary to the media focus on 
inherited mutations, only 5 to 10% of all cases of cancer are traced 
 
39.  See Song Wu et al., Substantial Contribution of Extrinsic Risk Factors to 
Cancer Development, 529 NATURE 43 (2016); MALKAN, supra note 20. 
40.  See generally Taylor Kraus, Caring About Personal Care Products: Regula-
tion in the United States, The European Union, and China in the Age of 
Global Consumption, 33 WIS. INT’L L.J. 167, 177 (2015); Pearson, supra note 
27; Valerie J. Watnick, Our Toxins Regulatory System and Why Risk Assess-
ment Does Not Work: Endocrine Disrupting Chemicals as a Case in Point, 
2004 UTAH L. REV. 1305, 1307 (2004) [hereinafter Watnick I]; Berfield et al., 
supra note 3. 
41.  SAMUEL S. EPSTEIN, NATIONAL CANCER INSTITUTE AND AMERICAN CANCER 
SOCIETY: CRIMINAL INDIFFERENCE TO CANCER PREVENTION AND CONFLICTS OF 
INTEREST 7 (2011); PRESIDENT’S CANCER PANEL, supra note 9, at 4–5; Janet 
Nudelman et al., Policy and Research Recommendations Emerging from the 
Scientific Evidence Connecting Environmental Factors and Breast Cancer, 
15(1) INT’L J. ENVTL. & OCCUPATIONAL HEALTH 79, 79–80 (2009); Valerie J. 
Watnick, The Missing Link: Regulation of Consumer Cosmetic Products to 
Protect Human Health and the Environment, 31 PACE ENVTL. L. REV. 595, 
612–13 (2014) [hereinafter Watnick II].  
42.  PRESIDENT’S CANCER PANEL, supra note 9, at i. 
43.  Annualized Mean Net Costs of Care, NAT’L CANCER INST., 
https://perma.cc/4TBF-M3ZT.  
44.  Feelings and Cancer, NAT’L CANCER INST. (Dec. 2, 2014), 
https://perma.cc/PD42-UW66. 
45.  Cancer Survivors: Late Effects of Cancer Treatment, MAYO CLINIC, 
https://perma.cc/JJ5S-QUHU. 
9
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to inherited genetic mutations, whereas a substantial percentage 
of the remaining risk can be attributed to environmental and life-
style factors.46 In 2010, the President’s Cancer Panel released its 
report, Reducing Environmental Cancer Risk, which called atten-
tion to the contribution of environmental toxicants to the develop-
ment of cancer.47 The President’s Cancer Panel noted a variety of 
current shortcomings relating to toxicity testing and the ineffective 
regulation of toxicants. The Panel also observed that corporations 
have exploited the current risk-based regulatory approach that 
permits manufacturers to use toxicants in cosmetic products while 
placing the burden on the public and the corresponding regulatory 
agency to demonstrate conclusive harm.48 These numerous defi-
ciencies, according to the report, run contrary to a fundamental 
principle underlying public health policy: it is far more effective to 
prevent cancer than to treat it.49 
2.  Common Toxicants in Cosmetic Products 
 Toxicants in personal care products are numerous,50 scientif-
ically troubling,51 and present in even the smallest of members of 
the population: neonates.52 According to surveys conducted by the 
Campaign for Safe Cosmetics, a consumer advocacy organization, 
the average person uses 12 cosmetic products and will be exposed 
to 126 chemicals on a daily basis.53 These chemicals are inhaled, 
ingested, and absorbed into the body.54 Data from the National Bi-
omonitoring Program conducted through the Centers for Disease 
 
46.  The Genetics of Cancer, NAT’L CANCER INST. (last updated May 1, 2017), 
https://perma.cc/LT95-LA3Q. 
47.  PRESIDENT’S CANCER PANEL, supra note 9. 
48.  Id. at ii–viii, 19, 99. 
49.  Id. at 97. 
50.  RASANAYAGAM ET AL., supra note 5, at 7. 
51.  See DELLAVALLE, supra note 7, at 6, 11. 
52.  Id. at 7; Philippa Darbre & Philip Harvey, Parabens Can Enable Hallmarks 
and Characteristics of Cancer in Human Breast Epithelial Cells: A Review 
of the Literature With Reference to New Exposure Data and Regulatory Sta-
tus, 34 J. APPLIED TOXICOLOGY 925 (2014); Nudelman et al., supra note 41, 
at 80, 82, 88–89; Rachael Rawlins, Teething on Toxicants: In Search of Reg-
ulatory Solutions for Toys and Cosmetics, 20 FORDHAM ENVTL. L. REV. 1, 2, 
4–6 (2009).  
53.  RASANAYAGAM ET AL., supra note 5, at 7. See generally SARANTIS ET AL., supra 
note 5. 
54.  SARANTIS ET AL., supra note 5, at 3, 6, 22. 
10https://digitalcommons.pace.edu/pelr/vol35/iss1/2
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Control and Prevention found more than 260 environmental chem-
icals present in the human body, many of which have also found 
their way to developing fetuses.55 When pregnant women use cos-
metic products, these toxicants seep into umbilical cord blood and 
across the placenta, pre-polluting society’s youngest and most vul-
nerable.56 
Scientific evidence has not only mounted against ingredients 
such as talc57 but also against many others commonly found in cos-
metics that belong to a class of chemicals scientists refer to as en-
docrine disrupting chemicals (“EDCs”). Such EDCs include para-
bens, a class of preservatives;58 phthalates, a plasticizer;59 and 
Perfluorooctanoic acid (“PFOA”).60 Scientists believe EDCs disrupt 
normal hormone activity by blocking or mimicking the effect of hor-
mones, which alters the course of an organism’s growth and devel-
opment.61 EDCs can mimic estrogen62 and have been linked to the 
development of cancer.63 Research has also demonstrated a link 
between EDCs and decreased sperm count; breast, testicular, and 
prostate cancer; and neurological disorders.64 
 
55.  See FOURTH NATIONAL REPORT, supra note 6; UPDATED TABLES, supra note 6. 
56.  DELLAVALLE, supra note 7; Darbre & Harvey, supra note 52; Nudelman et 
al., supra note 40, at 82–83, 88; Rawlins, supra note 52, at 2. 
57.  See Daniel W. Cramer et al., Genital Talc Exposure and Risk of Ovarian 
Cancer, 81 INT’L J. CANCER 351 (1999).   
58. Shawn Pan et al., Parabens and Human Epidermal Growth Factor Receptor 
Ligand Cross-Talk in Breast Cancer Cells, 124(5) ENVTL. HEALTH PERSP. 563 
(2016); Darbre & Harvey, supra note 52; Kraus, supra note 40, at 171–73; 
Watnick II, supra note 41, at 615–16. 
59.  LISA ARCHER ET AL., CAMPAIGN FOR SAFE COSMETICS, A LITTLE PRETTIER: 
COSMETIC COMPANIES DENY HEALTH PROBLEMS RELATED TO PHTHALATES, BUT 
ARE THEY SECRETLY REFORMULATING? 3 (2008), https://perma.cc/444U-
63AU; JANE HOULIHAN ET AL., ENVTL. WORKING GROUP, NOT TOO PRETTY: 
PHTHALATES, BEAUTY PRODUCTS & THE FDA (2002), https://perma.cc/W264-
W7P2; PRESIDENT’S CANCER PANEL, supra note 9, at 23, 38–40; SARANTIS ET 
AL., supra note 5; Kraus, supra note 40, at 171–73; Rawlins, supra note 52, 
at 4–5. 
60.  See RASANAYAGAM ET AL., supra note 5.  
61.  Watnick II, supra note 41, at 608. 
62.  PRESIDENT’S CANCER PANEL, supra note 9, at 2–3; Rawlins, supra note 52, at 
4–5, 12–15; Watnick I, supra note 40, at 1307–10; Watnick II, supra note 41, 
at 606–09, 614–22.  
63.  PRESIDENT’S CANCER PANEL, supra note 9, at 3, 22, 38; see Watnick II, supra 
note 41, at 608–09, 612–22. 
64.  PRESIDENT’S CANCER PANEL, supra note 9, at 38; Watnick I, supra note 40, 
at 1308–09. 
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III.  THE CURRENT RISK-BASED REGULATORY 
FRAMEWORK 
A. Regulation of Cosmetics by the FDA 
Contrary to common public opinion,65 the FDA does not assess 
the safety of ingredients in cosmetics prior to their entry into the 
marketplace. Instead, regulatory policy pertaining to cosmetics fol-
lows a risk-based approach whereby the FDA presumes the prod-
uct and all ingredients contained therein “safe” unless there is in-
controvertible proof of harm.66 In 1938, Congress passed the 
Federal Food, Drug, and Cosmetic Act (“FDCA”), which granted 
the FDA the authority to regulate cosmetics.67 Yet, current regu-
lations are minimal, contain numerous loopholes, and lack author-
ity for meaningful product oversight. 
The FDCA defines “cosmetics” as “articles intended to be 
rubbed, poured, sprinkled, or sprayed on, introduced into, or oth-
erwise applied to the human body . . . for cleansing, beautifying, 
promoting attractiveness, or altering the appearance.”68 This defi-
nition encompasses a lengthy list of personal care products such as 
makeup, shampoo, hairspray, aftershave, shaving cream, deodor-
ant, lotion, baby products, and perfume.69 Manufacturers have a 
responsibility to ensure the safety of their products, but the FDA 
does not require specific tests or data relating to product safety 
from manufacturers.70 The FDA does not conduct any pre-market 
review of the final product or its ingredients to assess either short- 
or long-term adverse health effects, and there is no mandated pro-
spective determination of safety before the product enters the mar-
ket.71 
 
65.  See Berfield et al., supra note 3. 
66.  Carl Cranor, Do You Want to Bet Your Children’s Health on Post-Market 
Harm Principles?, 19 VILL. ENVTL. L.J. 251, 275–76 (2008); S. Lochlann Jain, 
Fear of Cancer, 44 LOY. L.A. L. REV. 233, 239 (2010); Kraus, supra note 40, 
at 173–75; Rawlins, supra note 52, at 9–16. 
67.  See Federal Food, Drug, and Cosmetic Act of 1938 (“FDCA”) § 1, 21 U.S.C. 
§ 301 (2012). 
68.  FDCA § 201(i). 
69.  Id. § 201. 
70.  Kraus, supra note 40, at 176–77; Rawlins, supra note 52, at 9–15; FDA Au-
thority Over Cosmetics, supra note 4. 
71.  Kraus, supra note 40, at 176–77; Rawlins, supra note 52, at 9–15; Watnick 
II, supra note 41, at 601–03; FDA Authority Over Cosmetics, supra note 4. 
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Under the FDCA, manufacturers are prohibited from market-
ing adulterated or misbranded cosmetics.72 The FDCA defines 
“adulteration” as “violations involving product composition” that 
include “ingredients, contaminants, [and] processing” that would 
result in the product containing a “poisonous or deleterious sub-
stance which may render it injurious to users . . . .”73 Misbranding 
refers to violations for lack of accurate and proper labeling, which 
includes listing ingredients in a manner that is false or misleading, 
failing to list ingredients or material facts about the product, or 
failing to include warning statements.74 Despite these require-
ments, legal scholars have noted the difficulty of determining what 
constitutes a product that would be injurious to users given man-
ufacturers’ vested financial interest in proclaiming the product’s 
safety.75 In theory, the provision pertaining to adulterated and 
misbranded cosmetics prevents manufacturers from marketing a 
cosmetic that is harmful to consumers when the consumer uses the 
product as intended.76 
However, failing to define what constitutes “harmful” presents 
a substantial shortcoming.  For toxicants that do not cause an im-
mediate and severe reaction but rather subtle effects, latent harm, 
and increased risk of disease, the definition of an “adulterated” 
product becomes murkier—and, thus, warrants re-envisioning cur-
rent limitations on the definition of “injurious.” That is, if a cos-
metic’s ingredients cause serious latent harms such as the in-
creased risk of cancer from EDCs, they should be prohibited under 
the adulteration provision—even if the cosmetic’s ingredients 
would not cause immediate and visible injury. Re-envisioning the 
definition of “injurious” would also require a corresponding change 
in prohibitions against misbranding and require manufacturers to 
list harmful ingredients on labels or warn of such risks. 
Currently, there are several mechanisms to track products 
and data, both through the FDA as well as the cosmetic industry’s 
trade association, the Cosmetic Ingredient Review (“CIR”) Panel.77 
 
72.  FDCA §§ 601–02. 
73.  Id. § 601. 
74.  Id. § 602. 
75.  Rawlins, supra note 52, at 9–15. 
76.  Id.; FDA Authority Over Cosmetics, supra note 4. 
77.  Cosmetic Ingredient Review Expert Panel, COSMETICS INFO, 
http://perma.cc/E75E-BALB [hereinafter Cosmetic Ingredient Review]. 
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The FDA utilizes a system for manufacturers to register their prod-
ucts, but this registration is voluntary, rather than required.78 
Combining voluntary registration with a lack of pre-market review 
means manufacturers have little incentive to submit data to the 
FDA about their products’ ingredients.79 Manufacturers may also 
voluntarily submit their data to CIR, which can assess the safety 
of ingredients.80 Recent estimates show only 11 to 13% of all ingre-
dients in cosmetics have been subjected to CIR’s analysis, and 
since CIR’s inception in 1976, it has concluded lack of safety for 
only 11 out of the more than 10,000 chemicals currently used in 
cosmetics.81 Finally, CIR is an industry-funded organization, 
which raises conflict of interest concerns relating to the potential 
for lack of impartial self-regulation.82 
In addition to the shortage of data on product safety, the cur-
rent system also lacks transparency relating to basic disclosure of 
product ingredients. The FDCA contains numerous loopholes that 
permit manufacturers to omit potentially harmful cosmetic ingre-
dients from the product label.83 Under the FDCA, manufacturers 
are not required to list the composition of ingredients under the 
headings “fragrance” or “flavor,” although both may contain EDCs; 
manufacturers may claim such ingredients constitute a protected 
trade secret.84 Thus, although EDCs may be present in products, 
they may not be listed on product labels. This leaves consumers 
unaware of many products’ ingredients and the health risks of us-
ing those products.85 
Two consumer advocacy groups, the Campaign for Safe Cos-
metics and the Environmental Working Group, have conducted 
several independent investigations which found that the ingredi-
ent labels for many common products such as perfume, face cream, 
and lotion did not list phthalates despite their presence in 75% of 
 
78.  FDA Authority Over Cosmetics, supra note 4. 
79.  Shah & Taylor, supra note 27, at 225–27; Watnick II, supra note 41, at 604–
06. 
80.  Rawlins, supra note 52, at 10–13; Watnick II, supra note 41, at 604–06, 622–
26; Cosmetic Ingredient Review, supra note 77.  
81.  Watnick II, supra note 41, at 605–06. 
82.  Id.; Rawlins, supra note 52, at 11–12. 
83.  Rawlins, supra note 52, at 6–7, 10–13; Shah & Taylor, supra note 27, at 224–
28. 
84.  Shah & Taylor, supra note 27, at 227–28.   
85.  RASANAYAGAM ET AL., supra note 5; SARANTIS ET AL., supra note 5.  
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the products tested.86 Manufacturers may also decline to list an 
ingredient on a label if the ingredient is designated as a contami-
nant of another ingredient.87 In one independent investigation, the 
Campaign for Safe Cosmetics tested products such as anti-aging 
face creams, makeup, and shaving cream—all of which contain Pol-
ytetrafluoroethylene (“PTFE”), which creates a sleek and smooth 
finish.88 PFOA, a contaminant in PTFE linked to cancer, endocrine 
disruption, and reproductive harm, was not listed on the label for 
the products that contained it in these independent tests.89 A prod-
uct may also contain an ingredient that releases chemicals into the 
air during the normal course of use but that the manufacturer does 
not list on the label. In 2012, the media reported that Johnson & 
Johnson’s “Johnson’s Baby Shampoo” formulation contained qua-
ternium-15—a preservative that releases formaldehyde which, in 
2004, IARC determined is carcinogenic to humans.90 Failing to 
fully and accurately disclose ingredients on the label makes it ex-
ceedingly difficult for consumers to buy products without harmful 
toxicants. 
Even if consumers become aware of a product’s adverse effects, 
the FDA has no authority to order a recall of the product.91 If the 
FDA determines that a product is adulterated or misbranded, the 
FDA may issue a Warning Letter to the manufacturer indicating 
the manufacturer’s regulatory noncompliance or request that the 
Department of Justice intervene.92  Such an attempt to alert con-
sumers, contact the Department of Justice to initiate a complaint 
against the manufacturer, and obtain a judicial ruling to remediate 
the danger constitutes a more challenging proposition. It also 
raises questions about the sufficiency of the FDA’s ability to shield 
 
86.  HOULIHAN ET AL., supra note 59, at 1–2. 
87.  RASANAYAGAM ET AL., supra note 5, at 18. 
88.  Id. at 8, 10.   
89.  Id. at 8, 12.  
90.  MALKAN, supra note 20, at 4–10; Katie Thomas, The ‘No More Tears’ Sham-
poo, Now With No Formaldehyde, N.Y. TIMES (Jan. 17, 2014), 
https://perma.cc/T76B-TA9K; Press Release, International Agency on Can-
cer Research, IARC Classified Formaldehyde as Carcinogenic to Humans 
(June 15, 2004), https://perma.cc/RB3X-GCG9. 
91.  FDA Authority Over Cosmetics, supra note 4. 
92.  Id.; Letter from Michael Roosevelt, Acting Director, CFSAN Off. of Compli-
ance, to Mike Brady, CEO, GIB, LLC dba Brazilian Blowout (Aug. 22, 2011), 
https://perma.cc/5WS9-MXUZ. 
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consumers from cosmetics with high levels of carcinogens that 
cause immediate adverse health reactions. 
B. Limitations of the FDCA and Implications for 
Consumers 
The impact of these ineffectual provisions became apparent 
several years ago when a new product called Brazilian Blowout in-
undated salons as a chemical treatment designed to straighten 
women’s hair.93 While women raved about their newly smooth 
hair, salon workers started to report serious physical reactions to 
the chemical straightening product in droves. Such reported reac-
tions included burning throats, stinging eyes, blistering rashes, 
and breathing difficulty.94 Despite Brazilian Blowout’s manufac-
turer—GIB, LLC—explicitly advertising its product as “formalde-
hyde free,” it contained a liquid form of formaldehyde called meth-
ylene glycol.95 GIB argued in a subsequent lawsuit that methylene 
glycol did not equate to formaldehyde, even though the product re-
leased dangerously high levels of formaldehyde when used as in-
tended.96 Specifically, the Occupational Safety and Health Admin-
istration found that Brazilian Blowout products released 
approximately five times the acceptable workplace limit of formal-
dehyde.97 An official with the California Department of Public 
Health confirmed that “[c]osmetic products that contain known hu-
man carcinogens or chemicals that impair human reproduction or 
development are marketed and sold without adequate safety tests 
 
93.  Jane Kay et al., U.S. Government Has Little Authority to Stop Unsafe Cos-
metics, SCIENTIFIC AMERICAN (Oct. 18, 2012), http://perma.cc/WL4S-SSKY.   
94.  Id.  
95.  Hair-Smoothing Products that Release Formaldehyde when Heated, FDA, 
https://perma.cc/WD77-3RY3 (last updated Nov. 3, 2017); Hair Smoothing 
Products that Could Release Formaldehyde, OSHA, https://perma.cc/CU2Q-
ZYRD. 
96. Second Am. Compl. & Demand for Jury Trial, In re Brazilian Blowout Litig., 
No. 10-8452 JFW (C.D. Cal. Nov. 5, 2010); Consent Judgment, People v. GIB, 
No. RG10545880 (Cal. Super. Ct. Jan. 5, 2012); Press Release, Cal. Dep’t of 
Justice Office of the Att’y Gen., Attorney General Kamala D. Harris An-
nounces Settlement Requiring Honest Advertising Over Brazilian Blowout 
Products (Jan. 30, 2012), https://perma.cc/WQ3T-HH52 [hereinafter Attor-
ney General Press Release on Brazilian Blowout]. 
97.  Kay et al., supra note 93. 
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because the . . . law allows it.”98 Moreover, in referencing Brazilian 
Blowout, this official stated that “the levels of formaldehyde ex-
ceeded levels that would be of concern for causing cancers and 
short-term effects.”99 
Although the California Attorney General announced a settle-
ment against the manufacturer, the terms of the settlement were 
primarily confined to re-labeling the product and modifying adver-
tising to indicate the risk associated with use.100 The product thus 
remained on the market—but merely with an updated label.101 
This raised the question of the label’s sufficiency in protecting cos-
metics consumers from dangerous levels of toxicants; they may 
continue to use the product without understanding either its warn-
ing label’s implications or the level of associated risk.102 
As the President’s Cancer Panel observed, the current regula-
tory framework for cosmetics is both outdated and ineffective. The 
FDCA ultimately fails to ensure the safety of products that enter 
the marketplace, permits products with known carcinogens onto 
store shelves, and lacks the authority to remove products posing 
substantial risks.103 Importantly, attempting to regulate the cos-
metics industry product by product is piecemeal and inefficient. 
Legal and regulatory interventions should not be contingent upon 
public outcry when a product generates serious adverse health out-
comes in its users.104 
Augmenting these shortcomings associated with lack of re-
quired product review, FDA’s risk-based framework equivocates 
potential risks in its consumer product information. For example, 
FDA’s consumer information pertaining to EDCs such as 
phthalates states that “[i]t’s not clear what effect, if any, 
phthalates have on human health,” and that, “[a]t the present 
time, FDA does not have evidence that phthalates as used in cos-
metics pose a safety risk.”105 Similarly, FDA’s consumer 
 
98.  U.S. Government Has Little Authority to Stop Unsafe Cosmetics, SCIENTIFIC 
AMERICAN (Oct. 18, 2012), https://perma.cc/W454-RYWB.  
99.  Id.  
100. Attorney General Press Release on Brazilian Blowout, supra note 96.  
101. Amy Westervelt, Brazilian Blowout Legally Labeled Carcinogenic . . . Will 
It Matter?, FORBES (Jan. 30, 2012, 9:18 PM), https://perma.cc/P88Z-3ED5. 
102. Id. 
103. PRESIDENT’S CANCER PANEL, supra note 9, at i, ii, xiii, 2, 19, 99. 
104. See Shah & Taylor, supra note 27, at 205, 207–08, 216, 220. 
105. Phthalates, FDA, https://perma.cc/REF8-7HBH (last updated Oct. 5, 2016). 
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information page for parabens claims that the FDA “[does] not 
have information showing that parabens as they are used in cos-
metics have an effect on human health.”106 Although such state-
ments are aligned with the standards governing the current risk-
based regulatory framework, it likely compounds the consumer’s 
belief that these assertions equate to product safety. 
C. Cultivating Consumer Confusion 
Consumers who attempt to gain clarity about product risk or 
safety information from sources such as the manufacturer or CIR 
will encounter grossly inaccurate representations made on each’s 
websites.107 These descriptions do not merely reflect the risk-based 
framework but rather undermine and mischaracterize the availa-
ble data and scientific consensus. Cosmetics giant Proctor & Gam-
ble asserts that its products contain parabens and phthalates at 
levels well below safe ranges, that the body easily breaks down and 
eliminates these chemicals, and that these chemicals have been 
thoroughly studied and found to be safe.108 Reports by the Presi-
dent’s Cancer Panel, the Environmental Working Group, and the 
Campaign for Safe Cosmetics, as well as independent scientific re-
search, contradict these inaccurate statements, finding instead a 
lack of safety and mounting cause for concern.109 These statements 
also mischaracterize the U.S. regulatory risk-based system be-
cause the FDA has not made any safety determination but rather 
requires a high evidentiary bar demonstrating risk before declar-
ing a product potentially harmful.110 
 
106. Parabens in Cosmetics, FDA, https://perma.cc/MM6L-QNMK (last updated 
Oct. 5, 2016). 
107. About Us, COSMETICS INFO, https://perma.cc/9KC5-SXDF; Cosmetic Ingredi-
ent Review, supra note 77; How Cosmetics Are Regulated in the US, 
COSMETICS INFO, https://perma.cc/PEH4-SKUG; Parabens, PROCTOR & 
GAMBLE, https://perma.cc/H35K-3FJN; Phthalates, PROCTOR & GAMBLE, 
https://perma.cc/X87R-UVYG. 
108. See Parabens, supra note 107; Phthalates, supra note 107.  
109. ARCHER ET AL., supra note 59; Crews & Gore, supra note 12; DELLAVALLE, 
supra note 7; HOULIHAN ET AL., supra note 59; PRESIDENT’S CANCER PANEL, 
supra note 9; RASANAYAGAM ET AL., supra note 5; SARANTIS ET AL., supra note 
5; Anway et al., supra note 12; Darbre & Harvey, supra note 52; Rozek et 
al., supra note 12;. 
110. Watnick I, supra note 40, at 1329–30; Cranor, supra note 66, at 281–82. 
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Similarly, the industry-funded CIR states that “[c]osmetic 
companies’ strong commitment to safety has made cosmetic and 
personal care products among the safest product categories regu-
lated by the FDA,” and that manufacturers perform rigorous test-
ing.111 The CIR further claims that any adverse reactions are re-
lated to mere allergies or rashes and that the FDCA requires every 
cosmetic and its ingredients to be substantiated for safety before 
going to market.112 CIR’s statement alluding to testing impartial-
ity and thoroughness could be misinterpreted as stringent safe-
guards against harmful products’ entry into the market. Further, 
numerous legal scholars and consumer advocacy groups have 
called attention to the lack of rigor in product oversight for cosmet-
ics and its resulting adverse health impact.113 
Manufacturer defenses pertaining to the nature of their prod-
ucts closely track those employed by Big Tobacco several decades 
ago.114 The documentary The Human Experiment discusses how 
public relations teams strategically manufacture doubt to under-
mine allegations within the scientific community about the true 
risk associated with product use.115  Such methods include creating 
distraction, employing deception, using strategic marketing, and 
skewing science.116 A variety of cosmetic manufacturers appear to 
employ this model. First, by donating to the American Cancer So-
ciety and strategically marketing their involvement in finding a 
“cure” for cancer, these corporations purposely distract from the 
policy paradox that the majority of cancer is caused by environ-
mental toxicants like those found in the cosmetics these corpora-
tions manufacture.117 Second, assertions by manufacturers such as 
Proctor & Gamble that parabens and phthalates are eliminated by 
the body and have been proven safe inaccurately—and 
 
111. How Cosmetics Are Regulated in the US, supra note 107. 
112. About Us, supra note 107; Cosmetic Ingredient Review, supra note 77; How 
Cosmetics Are Regulated in the US, supra note 107.  
113. See, e.g., Rawlins, supra note 52; sources cited supra note 109. 
114. DEVRA DAVIS, THE SECRET HISTORY OF THE WAR ON CANCER 3, 9–12 (2007) 
(ebook); EPSTEIN, supra note 41, at 116–17, 118–32. 
115. THE HUMAN EXPERIMENT (Area 23a 2013). 
116. Id.  
117. PINK RIBBONS, INC. (First Run Features 2011); Poison Isn’t Pretty, BREAST 
CANCER ACTION, https://perma.cc/4YJG-3PM3; Karuna Jagger, Why the 
American Cancer Society Must Take A Stronger Stand Against Cancer Pre-
vention, HUFFINGTON POST (Nov. 3, 2015, 9:39 AM), https://perma.cc/H7MS-
H38P.  
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deceptively—skew the scientific consensus.118 Public health schol-
ars such as Devra, Davis, and Epstein have extensively researched 
and commented on this disconnect between public messaging em-
ployed by manufacturers who support research to cure cancer 
while “hiding or stifling evidence that their own products caused 
the disease.”119 
D. Conflicts of Interest and the American Cancer 
Society 
Problematically, for consumers particularly motivated to in-
vestigate whether cosmetics increase their risk of preventable dis-
ease, turning to the American Cancer Society’s (“ACS”) consumer 
information echoes the deceptive industry tagline. Both Davis and 
Epstein have meticulously detailed the substantial funding the 
ACS receives from the very companies that manufacture products 
containing environmental toxicants, including Johnson & Johnson, 
Avon, and Revlon.120 This creates immense conflicts of interest for 
the ACS when representing to the public the risk or safety of its 
donors’ products.121 On a consumer information web page on cos-
metics, ACS asserts that there are gaps in scientific evidence of 
whether cosmetics can cause health problems because there have 
been no long-term studies, it is unclear what chemicals are ab-
sorbed into the body, and epidemiological studies using animal 
models may inflate actual risk.122 The ACS also proclaims that 
“most scientists and regulatory agencies believe it is ‘very unlikely’ 
that cosmetic ingredients have serious health effects.”123 Each of 
these statements starkly contrasts the findings of the President’s 
Cancer Panel, the Halifax Project, and independent scientific as-
sessments. It is unacceptable that the ACS not only adopts the 
 
118. See Parabens, supra note 106; Phthalates, supra note 105. 
119. DAVIS, supra note 114, at 14. 
120. EPSTEIN, supra note 41, at 116; Acknowledging Corporate Support, 
AMERICAN CANCER SOCIETY, https://perma.cc/VKJ2-87TV. 
121. EPSTEIN, supra note 41, at 116; Acknowledging Corporate Support, supra 
note 120. 
122. Cosmetics, AMERICAN CANCER SOCIETY, https://perma.cc/PAY3-5YWB (last 
updated May 28, 2014). 
123. Id.  
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FDA’s risk-based model that equivocates the potential for harm 
but further mischaracterizes the scientific consensus.124 
E. Shortcomings of Risk-Based Approach and 
Adoption of Precautionary Approach 
Rather than relying on an ineffective risk-based approach that 
requires definitive proof of harm, both the President’s Cancer 
Panel and the United Nations General Assembly’s Rio Declaration 
affirmed that federal regulations, where practicable, should follow 
the precautionary principle—for example, manufacturers should 
submit data to the appropriate regulatory agency for pre-market 
review and approval.125 Instead of treating the American public as 
guinea pigs for determining the risks from toxicant exposures, if a 
toxicant raises a threat of harm to human health or the environ-
ment, the federal government should have a duty to enact precau-
tionary measures to mitigate such harm.126 As discussed below, 
scientific evidence affirms that EDCs pose a substantial threat to 
human health and that Congress should revise the FDCA to align 
with a precautionary model for cosmetics regulation. 
IV.  PROPERTIES OF EDCS 
A. How EDCs Operate 
The current risk-based model and extensive shortcomings in 
FDA regulations constitute an even greater concern when consid-
ering the impact of EDCs as a particular class of toxicants.127 Im-
plementing the precautionary principle becomes compelling con-
sidering that the President’s Cancer Panel also confirmed what 
scientists are discovering: EDCs challenge several traditional 
 
124. ARCHER ET AL., supra note 59; DELLAVALLE, supra note 7; HOULIHAN ET AL., 
supra note 59; PRESIDENT’S CANCER PANEL, supra note 9; RASANAYAGAM ET 
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notions of toxicity and risk.128 Most chemicals adhere to a stand-
ardized risk assessment—toxicology tests that follow a traditional 
dose-response curve which assumes that a lower amount of the 
chemical results in a lower risk of harm.129 EDCs, on the other 
hand, cause disruption at very low doses, including levels which 
scientists have not previously considered ecologically relevant.130 
Accordingly, traditional testing methods likely miss the risks pre-
sent at lower doses, and presuming minimal disruption based on 
exposure data from higher doses is also an inaccurate assessment 
of risk.131 Some experts theorize that there may be no threshold 
level of safety for EDCs but rather only varying scopes and severity 
of harm based on exposure.132 
The President’s Cancer Panel noted several additional limita-
tions of current toxicity testing that pose concerns for EDCs based 
on how toxicants accumulate, interact synergistically, and the tim-
ing of exposure. EDCs constitute a distinct class of toxicants which 
defies risk parameters established for traditional toxicity test-
ing.133 Many EDCs accumulate in the body and are stored in fat 
tissue.134 Each additional toxicant present in cosmetic products 
that we ingest, absorb, or inhale increases the amount of potential 
toxicants circulating or stored in the body at one time.135 The av-
erage individual encounters numerous toxicants throughout the 
course of the day, exposing the individual to multiple sources of 
phthalates, parabens, and other EDCs at one time in addition to 
increasing the total amount of toxicants within the body.136 Con-
current exposure can create a synergistic impact of each chemical; 
the interaction between toxicants can magnify the risks each poses 
alone.137 Stored toxicants may also interact with new exposures 
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such that both cumulative exposure and synergistic interaction 
shape the risk outcome.138 The full impact of these potential risks 
are not only unknown, but they are also unregulated because the 
United States does not currently utilize any mechanism to meas-
ure the synergistic impact of toxicants or assess acceptable limits 
on combined exposures.139 
B. The Hallmarks of Cancer 
The effects of EDCs may be subtle and variable, impacting a 
number of functions from the endocrine system and neurological 
functioning to fertility and risk of cancer.140 As with any chemical 
exposure, EDCs may influence individuals differently, increasing 
the unpredictability of reactions.141 Research demonstrates that 
EDCs exert genotoxic effects and can cause chromosomal damage, 
thereby increasing subsequent risk of disease including cancer.142 
A consortium of scientists working on the Halifax Project pro-
posed a fundamental paradigm shift to assess the contribution of 
environmental toxicants to the development of cancer and address 
the impact of the sheer amount of toxicant exposure.143 This con-
sortium concluded that instead of searching for toxicants that con-
stitute complete carcinogens, regulatory policy should assess 
whether chemicals induce what scientists call the “Hallmarks of 
Cancer.”144 This refers to how toxicants initiate a series of biologi-
cal changes including triggering inflammation and genomic insta-
bility, undermining immune function, and interfering with stages 
of cell division, death, and reproduction—multiple steps which, 
when combined, constitute what is labelled cancer.145 
Halifax Project scientists hypothesized that low doses of com-
mon chemicals can affect cancer-related mechanisms consumers 
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typically encounter in the environment.146 They also proposed that 
even if the chemicals cannot induce carcinogenesis on their own, 
they can function through bioaccumulation and synergy to over-
whelm the body’s defenses and initiate the multi-step process.147 
As one biologist summarized, the combined effect of chemicals on 
the Hallmarks of Cancer “explains why no single chemical has 
been linked consistently with breast cancer causation and probably 
never will be.”148 This, in the biologist’s view, “should not lead to a 
dismissal of any chemical as insignificant but more an appreciation 
of the complexity of . . . chemical mixtures.”149 Accordingly, we 
must assess the potential for each of these chemicals to initiate the 
Hallmarks of Cancer and envision risk within a cumulative and 
synergistic mindset. 
C. Vulnerable Populations: Pregnant Women, 
Fetuses, and Children 
Incorporating both the effects of EDCs and scientific 
knowledge of how toxicants affect us requires re-assessing risk—
specifically as it pertains to vulnerable populations. Even if manu-
facturers conduct independent testing, reference doses to deter-
mine acceptable risk do not account for scaling to society’s young-
est.150 Children are particularly vulnerable to toxicant exposure 
based on pediatric magnification151: their bodies are smaller, so the 
same dose of a toxicant is more concentrated in a child’s body;152 
children are slower to detoxify from harmful exposures;153 and 
they are less able to repair damage resulting from toxicant 
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exposure.154 Thus, exposing children to the same level of toxicants 
as adults results in greater risk and impact.155 
The impact of fetal exposure implicates each of the pediatric 
considerations, in addition to concerns about the timing of expo-
sure during crucial stages of early development. Pregnant women 
pass along their body burden of toxicants to the developing fetus 
during gestation.156 Scientists describe a period called the critical 
“window of vulnerability” or “window of susceptibility” during ges-
tation and early infancy, during which exposure to toxicants can 
alter normal development and manifest in acute or long-term 
health effects.157 The developing brain is more susceptible to injury 
because the blood-brain barrier that normally filters some toxi-
cants has not developed.158 During fetal development, the brain 
and fetal tissue undergo rapid maturation along a specific path-
way.159 Any exposure to toxicants during this crucial stage could 
halt or alter the normal course of neuronal development, proper 
fetal tissue differentiation, and the development of the immune 
system, leading to long-lasting—or even permanent—health is-
sues.160 This critical window of development requires heightening 
protection for pregnant women, developing fetuses, and infants in 
a manner proportionate to the increased risks they face.161 
In many cases involving fetal development, there is a long la-
tency period from the time of exposure to the onset of illness caused 
by the toxicant, and effects of fetal exposure may not only directly 
impact the individual but their offspring as well.162 Perhaps the 
best-known example of this phenomenon is the case of Diethylstil-
bestrol (“DES”). From the 1950s to the 1970s, physicians treated 
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pregnant women with DES, a synthetic estrogen, for decades be-
fore discovering some of the daughters and granddaughters ex-
posed to DES in utero developed rare and aggressive forms of vag-
inal and uterine cancer.163 Accordingly, the effects of EDCs may 
not only be subtle and long-term but also multigenerational.164 
V.  THE IMPLICATION OF TOXICANTS IN 
COSMETICS FOR EPIGENETICS AND 
TRANSGENERATIONAL EPIGENETICS 
A.  How Toxicants Induce Epigenetic and 
Transgenerational Epigenetic Damage 
The field of epigenetics offers insight on how toxicant exposure 
can alter our genome and act as a direct causal link to the subse-
quent onset of disease.165 Environmental interaction with our ge-
nome occurs from numerous sources including diet, stress, and en-
vironmental toxicants.166 Epigenetic changes occur above the 
genes either through methylation, altering histone proteins, or 
RNA interference, distorting how each gene is expressed.167 Fur-
ther, epigenetic alterations occur much more frequently than gen-
otoxic mechanisms and affect several processes relating to growth, 
development, and risk for future disease.168 Toxicants in cosmetic 
products can induce chemical DNA modifications, leaving marks 
that will affect whether and how the gene’s sequence is ex-
pressed.169 For example, epigenetic marks induced by environmen-
tal triggers such as EDCs may turn off tumor suppressor genes or 
turn on oncogenes, leading to cancer development in either case.170 
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Exposure to adverse agents during critical periods of develop-
ment enhances the potential for widespread and severe epigenetic 
damage.171 If a fetus’s developing epigenome is exposed to toxi-
cants such as EDCs in utero that induce harmful epigenetic marks, 
this process could derail fetal development and prevent the af-
fected cells from ever arriving at the intended optimal gene expres-
sion.172 As a result, the fetus could face lifelong health damage 
such as increased risk of cancer, decreased fertility, neurological 
deficits, and immune dysfunction.173 
Although some epigenetic changes are potentially reversible, 
identifying and attempting to correct epigenetic marks may be in-
effective or cause off-target effects.174 If epigenetic marks persist 
in the genome, they can be passed on to subsequent generations 
during fetal development.175 Epigenetic marks may also be im-
printed in the germline, which permanently re-programs future 
generations’ epigenome.176 At this point, removing the intervening 
toxicant will not restore the genome to its original state, and all 
subsequent generations will face a deficiently programmed genome 
that carries an increased risk for adverse health outcomes.177 
Thus, exposure to EDCs through daily and ongoing usage of cos-
metic products not only increases the current population’s risk for 
cancer and other health issues but can also induce germline 
transgenerational epigenetic damage, increasing future genera-
tions’ cancer potential—even if never exposed to the same toxic 
products. 
B. Legal and Policy Implications of Epigenetics and 
Transgenerational Epigenetics 
The legal and policy implications of the true impact of our cur-
rent risk-based framework for regulating toxicants in cosmetics 
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are staggering and far reaching.178 The existing regulatory frame-
work permits manufacturers to use toxicants such as EDCs—
which, as scientific research shows, causes epigenetic changes to 
the user and increases risk of serious, yet preventable, diseases 
like cancer. This framework also passes risk along to future gener-
ations through transmuting the genome, placing them at an in-
creased risk of cancer and other disease. This regulatory passivity 
is simply untenable and unsustainable. Further, representations 
by manufacturers, CIR, and the ACS that mischaracterize the cur-
rent state of research on EDCs are particularly egregious. These 
statements purposely—and falsely—assuage consumer concern 
about products that potentially induce irreversible, transgenera-
tional epigenetic damage for the sake of financial gain. 
C. An Ethical Duty to Protect the Genome 
In 1998, the United Nations General Assembly referred to the 
human genome as the common “heritage of humanity.”179 Yet, 
EDCs and other toxicants in cosmetics that induce transgenera-
tional damage to the genome limit one’s health and future poten-
tial before birth—even if that person never used the product con-
taining those toxicants.180 Legal scholars such as Mark Rothstein 
and Christopher Wiener have recognized the formidable threat ep-
igenetic damage poses to future generations’ health and the im-
portance of removing the threat.181 This suggests that the damage 
is preventable—and that we thus have an ethical duty to protect 
the human genome from such risk. However, the current regula-
tory framework and misrepresentations by manufacturers, CIR, 
and the ACS refuting harm from toxicants are fundamentally in-
compatible with embracing current science to protect the human 
genome from preventable, environmentally mediated damage. 
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VI.  SOLUTIONS FOR REFORM 
Legal scholars and legislators have proposed several solutions 
to remediate the current shortcomings of the risk-based regulatory 
framework governing cosmetics, ranging from private litigation 
and state regulation to retail oversight and overhauling federal 
rules. 
A. Private Litigation 
Currently, courts will consider injury from environmental tox-
icants only when the plaintiff can satisfy the substantial factor 
test—that is, there is reasonable medical probability that the 
plaintiff’s exposure to a toxicant is sufficient to cause the type of 
injury suffered.182 Generally, courts will only permit recovery 
when the plaintiff can demonstrate that toxic exposure not only 
caused an increased risk of disease but also created a present phys-
ical injury.183 
However, environmental toxicant jurisprudence offers a path-
way to assess epigenetic risk and classify epigenetic marks as pre-
sent physical injury where causation can be traced to cosmetic tox-
icant exposure.184 In Brafford v. Susquehanna Corp., a radiation 
exposure case, the court permitted plaintiffs’ evidence that subcel-
lular damage from radiation could be a cognizable injury, as this 
damage “operated to ‘cock the trigger’ of cancer in the future” and 
deprived plaintiffs “a degree of immunity which they had enjoyed 
prior to their exposure.”185 Similarly, in Werlein v. United States, 
where plaintiffs were exposed to contaminated water, the court 
considered subcellular damage as a present physical injury by ac-
knowledging that the toxicant could induce chromosomal damage, 
which adversely affects cardiovascular and immune function.186 
Thus, the epigenetic marks induced by toxicant exposure are the 
present physical injury, and plaintiffs should not be required to 
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further demonstrate latent traditional notions of harm.187 Accord-
ingly, cosmetics that contain EDCs sufficient to cause epigenetic 
marks that magnify health risks of adverse health outcomes such 
as cancer should constitute an ipso facto cognizable injury. In ad-
dition to standalone claims for epigenetic damage, plaintiffs could 
introduce claims of added expenses relating to medical monitor-
ing.188 
Considering the outcome in Hogans, juries in jurisdictions that 
recognize subcellular injury could spark a product-by-product, liti-
gation-initiated incentive for manufacturers to reduce the toxi-
cants contained in their products. Despite the potential for spur-
ring piecemeal positive changes, legal scholars have noted the 
inherent limits of using the tort law system to regulate environ-
mental toxicants due to factors including: difficulties with demon-
strating specific causation;189 courts’ desire to limit liability within 
immediate generations;190 and the struggle of identifying the con-
tributing source of a toxicant, particularly when multiple products 
contain the same ingredient.191 
B. State Law 
Some states, such as California, have enacted laws that im-
pose requirements for products sold within the state containing 
toxicants.192 In 2005, the California legislature passed the Califor-
nia Safe Cosmetics Act, which requires manufacturers to submit to 
the state information about their products that contain chemicals 
“known or reasonably anticipated to be a human carcinogen”193 as 
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well as ingredients that have some or clear evidence of adverse de-
velopmental or reproductive toxicity defined by the National Toxi-
cology Program.194 The Act also created a database run by the Cal-
ifornia Department of Public Health that provides this information 
to the public.195 
California has also taken steps to increase manufacturer 
transparency at the point of purchase through Proposition 65.196 
Proposition 65 requires manufacturers to use a warning label on 
consumer products that are “known . . . to cause cancer or repro-
ductive toxicity.”197 Although these two laws aim to increase over-
sight of toxic products and provide consumers with valuable infor-
mation, federal law exempts categories of ingredients such as 
“fragrances” and ingredient formularies that the manufacturer 
designates as trade secrets, permitting the undisclosed presence of 
EDCs in products.198 Additionally, California’s laws lack the au-
thority for pre-market review.199 Finally, the inherent nature of 
state regulations means these requirements only pertain to Cali-
fornia, which may create inconsistencies among the states. 
C.   Retail Regulation 
In 2013, Walmart and Target announced sustainable product 
initiatives designed to prompt major manufacturers of consumer 
products—including cosmetics—to disclose product formulations, 
reduce priority defined toxic ingredients, and reformulate products 
with less toxic alternatives.200 While a laudable effort, this retail 
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regulation still falls short, as demonstrated by the case of Bi-
sphenol A (“BPA”), an EDC used as a plasticizer and in epoxy resin 
canned food lining.201 In 2008, manufacturers began phasing out 
the use of BPA in selected consumer products with the presump-
tion that alternative formulations would pose less risk to consum-
ers.202 However, many reformulated products contain Bisphenol S, 
which emerging research suggests also acts an EDC and poses sim-
ilar risk concerns to BPA.203 This example demonstrates a number 
of limitations with retailer regulation. For instance, manufactur-
ers may simply replace toxicants with other chemicals with un-
known risk profiles, or even other chemicals also linked to risk of 
adverse health concerns.204 This leaves the toxic alternative in the 
marketplace for years until adequate proof of harm emerges. 
D.  Amending the FDCA 
Despite the positive intentions of these solutions, each has sig-
nificant shortcomings, and adequate reform requires uniform fed-
eral regulation for comprehensive and effective change. In 2015, 
Senator Dianne Feinstein introduced in Congress the Personal 
Care Products Safety Act, which would amend the FDCA to permit 
manufacturer registration and the FDA to slowly review priority-
listed chemicals based on risk.205 However, Senator Feinstein is 
not the first to introduce such legislation—and such previous at-
tempts have failed repeatedly.206 It is critical to develop a compre-
hensive regulatory framework that reviews risk assessment data 
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prior to a cosmetic product’s marketing. It is equally as crucial that 
this framework recognize the potential of toxicants such as EDCs 
to induce subcellular injury in the form of epigenetic harm, both 
present and transgenerational. Reactionary policies that respond 
in a fragmented, chemical-by-chemical manner are inefficient and 
leave consumers exposed to demonstrated toxicants or equally 
harmful alternatives. 
VII.  CONCLUSION 
Recent litigation against Johnson & Johnson over seemingly 
benign talc alerted the public to the unfortunate reality that the 
ingredients in cosmetic products we use daily are not FDA ap-
proved yet may expose us to adverse health risks. A growing body 
of research links cosmetic products containing potentially toxic in-
gredients—like talc and EDCs like parabens, phthalates, and 
PFOA—to an increased risk of cancer that is otherwise preventa-
ble. Although the FDA’s risk-based approach prohibits manufac-
turers from placing adulterated or misbranded products in the 
stream of commerce, the FDCA does not require that the FDA as-
sess the safety of the ingredients of cosmetics, and the FDA has no 
authority to recall demonstrably harmful cosmetics. Emerging sci-
entific knowledge of how EDCs function fundamentally challenges 
traditional notions of what constitutes acceptable risk; EDCs cause 
harm at low doses, accumulate, interact synergistically, and dis-
proportionately impact society’s most vulnerable: pregnant 
women, fetuses, and children. 
For the current generation, cancer rates will likely continue to 
increase unless we abandon our failed risk-based and reactionary 
regulatory approach in favor of a precautionary framework de-
signed to critically examine the role of toxicants in the Hallmarks 
of Cancer. Most problematically, consumer exposure to EDCs in 
cosmetics may induce permanent, transgenerational epigenetic de-
ficiencies that increase future cohorts’ risks of cancer, fertility is-
sues, neurological deficits, and immune dysfunction. It is impera-
tive that we re-envision a comprehensive regulatory model that 
recognizes the dangers of failing to adopt the precautionary princi-
ple for ingredients in cosmetics. 
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